A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
A phase 1/2 trial of AP402 (Part 1 Dose esclation) in advanced solid tumours, run by AP Biosciences Inc., now recruiting.
Overview
A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06669975 by AP Biosciences Inc., with 85 participants planned, started 2025-04-22 and due to reach its primary completion in 2026-12-01. Interventions recorded: AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion).
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
Shares AP Biosciences and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.